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The thiol-disulﬁde oxidoreductase thioredoxin-1 (Trx1)
is known to be secreted by leukocytes and to exhibit
cytokine-like properties. Extracellular effects of Trx1 require
a functional active site, suggesting a redox-based mechan-
ism of action. However, speciﬁc cell surface proteins and
pathways coupling extracellular Trx1 redox activity to
cellular responses have not been identiﬁed so far. Using
a mechanism-based kinetic trapping technique to identify
disulﬁde exchange interactions on the intact surface of
living lymphocytes, we found that Trx1 catalytically inter-
acts with a single principal target protein. This target
protein was identiﬁed as the tumor necrosis factor receptor
superfamily member 8 (TNFRSF8/CD30). We demonstrate
that the redox interaction is highly speciﬁc for both Trx1
and CD30 and that the redox state of CD30 determines
its ability to engage the cognate ligand and transduce
signals. Furthermore, we conﬁrm that Trx1 affects CD30-
dependent changes in lymphocyte effector function. Thus,
we conclude that receptor–ligand signaling interactions
can be selectively regulated by an extracellular redox
catalyst.
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Introduction
Disulﬁde bonds have long been recognized as structural
elements stabilizing proteins in harsh extracellular environ-
ments. More recently, an additional concept has emerged:
some disulﬁde bonds operate as dynamic scaffolds capable of
regulated rearrangement into a variety of functional forms
(Jordan and Gibbins, 2006). Consistent with this notion,
various cell surface processes have long been known to
depend on catalyzed thiol-disulﬁde exchange including cell
adhesion (Essex, 2004), uptake of bacterial toxins (de Paiva
et al, 1993) and viral fusion with the host membrane
(Sanders, 2000). Moreover, a variety of cell surface signaling
receptors appear to exist in more than one thiol-disulﬁde
conﬁguration, for example CD28 (Greene et al, 1996).
However, in most cases, neither the catalyst driving thiol-
disulﬁde exchange nor the functional differences between the
redox forms have been elucidated.
A number of thiol-disulﬁde oxidoreductases are known to
be secreted and to act on the cell surface. One of these redox
catalysts is protein disulﬁde isomerase (PDI), a member
of the thioredoxin (Trx) superfamily. Cell surface-PDI has
been found to act on transmembrane and surface-associated
proteins, including the envelope protein of HIV-1, to cause
its fusogenic conformation (Markovic et al, 2004) and integrins,
to mediate platelet adhesion (Lahav et al, 2003). Another
thiol-disulﬁde oxidoreductase associated with extracellular
functions is Trx1. Best known for its intracellular roles,
Trx1 reduces transiently formed disulﬁde bonds of cytosolic
and nuclear target proteins and thereby participates in a
multitude of fundamental processes, ranging from oxidant
scavenging and DNA synthesis to regulation of apoptosis and
cell proliferation (Powis and Montfort, 2001). In addition,
Trx1 is released to the extracellular environment by a variety
of normal and neoplastic cells (Rubartelli et al, 1992). Human
Trx1 was ﬁrst puriﬁed as a cytokine-like factor from super-
natants of virally transformed lymphocytes and initially
named adult T-cell leukemia-derived factor (Tagaya et al,
1988), Tac-inducing factor (Tagaya et al, 1989), B-cell stimu-
latory factor or ‘B cell IL-1’ (Wakasugi et al, 1990).
Extracellular Trx1 is present in the circulation of healthy
subjects and its levels increase under inﬂammatory condi-
tions, including viral infection (Nakamura et al, 2001a).
Circulatory Trx1 acts as a chemoattractant for monocytes,
neutrophils and lymphocytes (Bertini et al, 1999), and
inhibits neutrophil migration into inﬂammatory sites both
in vitro and in vivo (Nakamura et al, 2001b). More recently,
Trx1 was found to be secreted by dendritic cells upon cognate
T-cell recognition and to contribute to subsequent T-cell
activation (Angelini et al, 2002).
At present, the mechanism(s) and pathway(s) by which
extracellular Trx1 inﬂuences cellular behavior remain un-
known. As many of its reported extracellular activities
depend on a functional active site, it appears likely that
Trx1 catalyzes thiol-disulﬁde exchange in one or more cell
surface target proteins through its enzymatic activity.
However, thiol-disulﬁde exchange reactions, even if highly
speciﬁc, are too transient to be detected by conventional
techniques. To date, only a single cell surface receptor, CD4,
a member of the immunoglobulin superfamily, has been
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3086shown to be susceptible to Trx1 redox activity (Matthias et al,
2002). Other cell surface proteins targeted by the enzymatic
activity of Trx1 await identiﬁcation.
In this study, we address the question as to which cell
surface receptors expressed on lymphocytes speciﬁcally
interact with extracellular Trx1 by way of disulﬁde bond
exchange. Using a kinetic trapping technique that enables
the detection and isolation of otherwise short-lived reaction
intermediates on the surface of intact cells, we identify and
validate the tumor necrosis factor receptor superfamily mem-
ber CD30 (TNFRSF8) as the principal target molecule for Trx1
on infected and transformed lymphocytes. The cell surface
activity of Trx1 is highly selective, discriminating between
different members of the TNFR superfamily. Trx1-mediated
thiol-disulﬁde exchange leads to a structural change in the
CD30 ectodomain that can be detected with conformation-
sensitive antibodies. We demonstrate that disulﬁde exchange
between Trx1 and CD30 interferes with binding of the CD30
ligand (CD30L) to its cognate receptor and that Trx1 affects
CD30-dependent changes in lymphocyte effector function. As
CD30 is implicated in both stimulatory and apoptotic signal-
ing, our ﬁndings suggest that Trx1 interacts with CD30 to
modulate lymphocyte behavior and survival under condi-
tions of infection and inﬂammation.
Results
To identify candidate Trx1 target proteins on the cell surface
of lymphoid cells, we applied a trapping technique based on
the reaction mechanism. This approach makes use of the
ﬁnding that mutant thiol-dependent oxidoreductases lacking
the C-terminal cysteine of the CXXC active site motif form
long-lived mixed disulﬁde intermediates with target proteins.
Thus, target proteins remain covalently linked to the mutant
oxidoreductase and become amenable to isolation and ana-
lysis (principle shown in Figure 1A). Kinetic trapping has
been applied previously to identify interaction partners of Trx
family members in plants (Motohashi et al, 2001) and in the
secretory pathway of human lymphocytes (Dick and
Cresswell, 2002; Dick et al, 2002). In these studies, the
CXXC-based trapping technique identiﬁed both established
and novel target proteins, subsequently conﬁrmed by inde-
pendent techniques, demonstrating the competence of this
technique to identify bona ﬁde interaction partners.
Mechanism-based kinetic trapping can be applied
to human Trx1
To determine whether kinetic trapping can be applied to
human Trx1, we created recombinant wild-type and mutant
Trx proteins, each equipped with a C-terminal dual afﬁnity
tag composed of a streptavidin-binding peptide (SBP) and a
hexahistidine tag. To create a trapping mutant, the second
cysteine of the
32CXXC
35 motif was replaced by serine (C35S).
Trx1 harbors three additional cysteine residues distal to the
active site (cysteines 62, 69 and 73). As these residues are
dispensable for catalytic activity but may cause oxidative
inactivation by either intra- or intermolecular disulﬁde bond
formation (Casagrande et al, 2002; Watson et al, 2003), we
also created mutants containing amino-acid substitutions for
those additional cysteines (Figure 1B; CCCCC, CCAAA,
CSCCC, CSAAA and SSAAA annotate the identity of residues
32, 35, 62, 69 and 73).
To test whether Trx1(C35S)-based trapping is capable of
identifying known Trx1 target proteins, Trx1(CSAAA) was
allowed to react with cytosolic proteins released from digitonin-
permeabilized cells. Incubation led to the formation of a
reproducible pattern of distinct mixed disulﬁde conjugates
as visualized by silver staining of a SDS–PAGE gel under non-
reducing conditions (Figure 1C, lane 7). In accordance with
the trapping mechanism, conjugation strictly depended on
the availability of the N-terminal thiol (Cys-32) and the
concurrent absence of the C-terminal thiol (Cys-35), as
wild-type or cysteine-free Trx1 did not capture any proteins
(Figure 1C, lanes 3, 5 and 9). The pattern of trapped proteins
was not signiﬁcantly inﬂuenced by the presence or absence of
the non-catalytic cysteines (data not shown). The main
cytosolic interaction partner of Trx1(CSAAA) was identiﬁed
as peroxiredoxin-1 (Prx1) by liquid chromatography tandem
mass spectrometry (LC-MS/MS). The Trx1–Prx1 association
was further conﬁrmed by immunoblotting (data not shown).
The Trx1–Prx1 disulﬁde-linked conjugate is maintained
under non-reducing conditions (Figure 1C, lane 7) and
cleaved into its monomer constituents under reducing condi-
tions (Figure 1C, lane 8).
To test whether Trx1(CSAAA) would also undergo authentic
interactions under conditions more typical of an extra-
cellular environment, we allowed Trx1(CSAAA) to react
with human plasma proteins. To avoid nonspeciﬁc absor-
bance to high-abundance serum proteins, we applied
Trx1(CSAAA) to a o30kDa plasma ultraﬁltrate, leading to
the capture of a small number of proteins, as visualized by
colloidal Coomassie staining (Figure 1D). Using LC-MS/MS,
the principal interaction partner from the plasma ultraﬁltrate
was identiﬁed as peroxiredoxin-2 (Prx2), a well-established
target protein of Trx1, recently found to be present in human
plasma (Chen et al, 2004). These experiments provided
proof-of-principle evidence that kinetic trapping is capable
of capturing and identifying proven target proteins of human
Trx1 from both intra- and extracellular environments.
Trx1 kinetic trapping is mediated by speciﬁc
protein–protein interactions
To further investigate whether the capture of proteins by
Trx1(CSAAA) is Trx-speciﬁc, we directly compared
Trx1(CSAAA) with the corresponding trapping mutant of
another member of the Trx superfamily, glutaredoxin-1
Grx1(CSAAA) (CSAAA annotates the identity of residues
22, 25, 7, 78 and 82). Grx1, like Trx1, uses its active site
thiol to act as a disulﬁde reductase in the cytosolic environ-
ment. However, in contrast to Trx1, Grx1 is specialized in the
recognition and reduction of protein–glutathione mixed dis-
ulﬁde bonds and forms mixed disulﬁde intermediates with
glutathione rather than with proteins (Yang et al, 1998;
Peltoniemi et al, 2006). As expected, we did not detect
trapping of peroxiredoxins (or other Trx1-interacting
proteins) by Grx1(CSAAA), neither on silver gels (Figure 1E,
lanes 3 and 4) nor by immunoblotting (data not shown). The
activity and thiol reactivity of the Grx1 trapping mutant was
conﬁrmed in independent experiments (data not shown),
thus demonstrating that the mere availability of an active
site thiol does not explain the proﬁle of proteins captured by
the Trx1 trapping mutant. Instead, our results support the
notion that Trx-mediated reducing activity is steered toward
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interactions.
Kinetic trapping can be applied to detect
Trx1 interactions on the cell surface
Having established the Trx1 kinetic trapping approach for
soluble target proteins, we asked whether the kinetic trapping
technique can also be applied to the surface of intact cells
in culture. Given previous indications of disulﬁde bond
exchange between CD4 and wild-type Trx1 (Matthias et al,
2002), we asked whether kinetic trapping would enable us to
detect this interaction on the surface of the CD4
positive promyelocytic cell line U937. In brief, we allowed
mutant Trx1 to interact with the surface of live cells,
removed unreacted oxidoreductase by washing and collected
disulﬁde-linked Trx1 complexes from cellular lysates by
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Figure 1 Mechanism-based kinetic trapping identiﬁes target proteins of human Trx1. (A) Catalytic mechanism of wild-type Trx1 (upper panel)
and the principle of substrate trapping (lower panel). The mixed disulﬁde intermediate is normally resolved by cysteine-35. Replacement of
cysteine-35 by serine (C35S) stabilizes the covalent intermediate. The afﬁnity tag enables puriﬁcation of resulting enzyme–substrate
complexes. (B) Schematic representation of recombinant Trx1 constructs. Catalytic (C
32,C
35) and structural cysteines (C
62,C
69,C
73)a r e
indicated. His6: hexahistidine tag; SBP: streptavidin-binding peptide. (C) Trapping of cytosolic Trx1 target proteins. Cytosolic proteins released
from digitonin-permeabilized Jurkat cells were incubated with different recombinant Trx1 proteins. Disulﬁde-linked Trx1 complexes were
analyzed by silver staining under non-reducing and reducing conditions. Trx1 complexes involving Prx1 and Prx2 are indicated; SAv
streptavidin. (D) Trapping of extracellular Trx1 target proteins. Trapping (CSAAA) and non-trapping (SSAAA) mutants of Trx1 were incubated
with a o30kDa fraction prepared from fresh human serum. Disulﬁde-linked complexes were analyzed by colloidal Coomassie staining under
non-reducing and reducing conditions. The Trx1–Prx2 conjugate and the Trx1 dimer as well as monomeric Prx2 and Trx1 are indicated.
(E) Kinetic trapping is mediated by speciﬁc protein–protein interactions. Cytosolic proteins from digitonin-permeabilized Jurkat cells were
incubated with SAv sepharose, Grx1(CSAAA) or Trx1(CSAAA). Disulﬁde-linked complexes were analyzed by silver staining under non-
reducing and reducing conditions. Trx1 conjugates formed with Prx1 and Prx2 are indicated. Other bands correspond to additional cytosolic
proteins interacting with Trx1.
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surface CD4 forms a mixed disulﬁde with exogenously added
Trx1(CSAAA) (Supplementary Figure S1, left panel), which
could be dissociated by DTT treatment (Supplementary
Figure S1, right panel). This result conﬁrmed that kinetic
trapping can indeed be used to identify speciﬁc Trx1-reactive
cell surface proteins and should therefore allow de novo
identiﬁcation of previously unknown cell surface target
proteins.
Kinetic trapping on the surface of lymphoid cell lines
identiﬁes a prominent Trx1 interaction partner
Human Trx1 was ﬁrst identiﬁed as an autocrine factor
secreted by and acting on virally transformed lymphoid cell
lines. We therefore applied cell surface trapping to a human
EBV-transformed lymphoblastoid B-cell line (LCL-721.220)
derived from the same parental cell line (LCL-721) as the
3B6 cell line, originally used in the description of the costi-
mulatory factor ‘3B6-IL1’, later identiﬁed as Trx1 (Wakasugi
et al, 1990). Mixed disulﬁde complexes, which formed on the
surface of LCL-721.220 cells were isolated and analyzed
by Trx1-speciﬁc immunoblotting to visualize overall mixed
disulﬁde conjugates. Interestingly, we found that Trx1 predomi-
nantly engages a single protein on the lymphoblastoid sur-
face, suggesting a highly selective interaction (Figure 2A, lane
3). As expected, the trapping product, a mixed disulﬁde
conjugate of about 160kDa, was susceptible to reduction
(Figure 2A, lane 4). The 160kDa conjugate did not form on
the surface of the EBV-negative Burkitts lymphoma cell line
BL-41 (Figure 2B). In contrast, a conjugate of the same size
was found to be formed on the surface of CCRF-CEM T cells
(Figure 2C) and YT large granular lymphoma cells (data not
shown). Pretreatment of the cell surface with the alkylating
agent iodoacetamide (IAA) did not interfere with the forma-
tion of the 160kDa mixed disulﬁde conjugate, thus conﬁrm-
ing that the conjugate was formed by the expected disulﬁde
exchange mechanism (rather than by de novo disulﬁde bond
formation between two thiol groups).
CD30/TNFRSF8 is the principal Trx1 sensitive receptor
on various lymphoid cell lines
To identify the unknown Trx1 target protein, we performed
cell surface trapping on a larger scale (5 10
9 LCL-721.220
cells), puriﬁed the Trx1-interacting surface protein by SAv
afﬁnity puriﬁcation and visualized the protein by colloidal
Coomassie staining (Figure 3A, left panel). The 160kDa band
was absent in the control precipitation with Trx1(CCAAA).
Corresponding bands from non-reducing and reducing lanes
were subjected to tryptic digestion and LC-MS/MS analysis.
From both samples the unknown protein was identiﬁed as
TNFRSF8 (CD30), a member of the TNFR superfamily. To
validate the direct covalent interaction between Trx1(CSAAA)
and CD30, an aliquot of trapped complexes from the same
experiment was separated under non-reducing and reducing
conditions and subjected to immunoblotting analysis with
anti-Trx1 (Figure 3A, middle panel) and anti-CD30 antibodies
(Figure 3A, right panel), respectively. The observed mobility
difference between non-reducing (NR) and reducing (R) lanes
demonstrated the formation of a mixed disulﬁde conjugate
(Figure 3A, right panel). Additional immunoblotting experi-
ments demonstrated that low nanomolar concentrations of
Trx1(CSAAA) are sufﬁcient to detect the interaction with
CD30 (Figure 3B) and also conﬁrmed that trapping of CD30
depends on the N-terminal cysteine of the CXXC motif
(Figure 3C, lanes 1–8). Application of the Grx1 trapping
mutant under the same conditions did not lead to its con-
jugation to CD30 (Figure 3C, lanes 9 and 10). Immunoblotting
and ﬂow cytometry experiments conﬁrmed that BL-41 cells,
unlike the other lymphocytic cell lines, do not express CD30
(Supplementary Figure S2), thus explaining the absence of
the 160kDa conjugate band (Figure 2B).
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Figure 2 Trx1 targets a single principal interaction partner on the surface of lymphocytic cell lines. (A) LCL-721.220 cells were incubated
with Trx1(CSAAA) and disulﬁde-linked complexes analyzed by anti-Trx1 immunoblotting under non-reducing and reducing conditions.
Cellular lysate was included as an immunoblotting control (Trx1*: endogenous Trx1). Dimerization of exogenously added Trx1 is indicated.
(B) LCL-721.220 or BL-41 B cells were treated as in (A). Trx1(CCAAA) was included as a control. Disulﬁde-linked complexes were analyzed as
in (A). (C) CCRF-CEM Tcells were treated as in (A) and complexes analyzed by anti-Trx1 immunoblotting under non-reducing and reducing
conditions. Conjugation of the unknown cell surface protein is indicated (Trx1-S-S-X).
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of the TNFR superfamily
Ectodomains of TNFR superfamily proteins typically are
composed of one to four cysteine-rich domains (CRDs),
each normally harboring three disulﬁde bonds (Bodmer
et al, 2002). To exclude the possibility that Trx1 interacts
with CRDs uniformly, we tested whether Trx1 discriminates
between distinct members of the TNFR superfamily. As
shown in Figure 4A, CD95 (TNFRSF6) did not form a
mixed disulﬁde conjugate with Trx1(CSAAA) on the same
cells under identical conditions. The same result was ob-
tained for the epidermal growth factor receptor (EGFR),
which contains a total of 25 ectodomain disulﬁde bonds,
and is expressed at substantial levels on A431 cells (Gill and
Lazar, 1981) (Figure 4B). These ﬁndings indicate that Trx1
reactivity of cell surface receptors is selective and is not
determined by the presence of CRDs or the number of
ectodomain disulﬁde bonds. To further exclude that Trx1
reactivity of receptors is determined or limited by surface
expression levels, we ectopically overexpressed CD30 or
other TNFR superfamily members under control of the
same promoter in HeLa cells and analyzed Trx1 cell surface
trapping by indirect immunoﬂuorescence. While mock-trans-
fected HeLa cells did not capture Trx1(CSAAA) on their
surface (Figure 4C, lower row), expression of CD30 led to a
strong Trx1 surface association and colocalization of both
proteins (Figure 4C, upper row). In contrast, expression of
CD95 (Figure 4D), TNFR1 or NGFR (data not shown) did not
promote Trx1 interactions with the cell surface, further
strengthening the notion that Trx1 reactivity is a speciﬁc
property of CD30.
The domain structure of human CD30 differs from other
members of the TNFR superfamily and from its murine
homologue by the presence of two additional CRDs, arising
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Figure 3 TNFRSF8/CD30 is the main Trx1 interaction partner on the surface of lymphoid cell lines. (A) A total of 5 10
9 LCL-721.220 cells
were incubated with Trx1(CSAAA) or Trx1(CCAAA) as control. Disulﬁde-linked Trx1 complexes were puriﬁed by SAv afﬁnity puriﬁcation and
analyzed by colloidal Coomassie staining under non-reducing and reducing conditions (left panel). Indicated bands were subjected to tryptic
digestion and LC-MS/MS analysis. In parallel, part of the same sample was analyzed by anti-Trx1 immunoblotting (middle panel). The blot was
stripped and reprobed with anti-human CD30 antibody (right panel). (B) CCRF-CEM T cells were incubated with different amounts of
Trx1(CSAAA) and disulﬁde-linked Trx1 complexes were analyzed by anti-CD30 immunoblotting under non-reducing and reducing conditions.
(C) CCRF-CEM Tcells were incubated with recombinant Trx1 constructs or the Grx1(C25S) trapping mutant as indicated and complexes were
analyzed as described in (B). The difference in signal intensity between non-reduced and reduced form of CD30 is due to less efﬁcient
recognition of the reduced form by the CD30-speciﬁc antibody.
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2004). We asked whether this unusual feature might confer
Trx1 reactivity to human CD30 and tested whether the shorter
murine CD30 could also interact with Trx1. As shown in
Figure 4E, murine CD30 expressed on the Rauscher murine
leukemia virus-induced T-cell lymphoma line RMA is efﬁ-
ciently targeted by Trx1(CSAAA), thus demonstrating that the
additional CRDs in human CD30 are not required for Trx1
reactivity. The result also suggests that the enzymatic afﬁnity
of Trx1 for CD30 has been conserved during mammalian
evolution.
Trx1 catalyzes disulﬁde bond reduction in CD30
and induces a conformational change disrupting
the Ki-1 epitope
To demonstrate by an independent method that Trx1 attacks
and breaks a disulﬁde bond in CD30, we used thiol-speciﬁc
cell surface biotinylation to verify that Trx1 activity generates
free thiols within the CD30 ectodomain (Supplementary
Figure S3). Subsequent analysis of CD30 cell surface expres-
sion by ﬂow cytometry and ﬂuorescence microscopy revealed
that a brief treatment of CD30
þ cells with wild-type Trx1 led
to the complete loss of CD30 recognition by the Ki-1 antibody
(Figure 5A, upper panel and Figure 5B, second column).
Similar results were obtained when another monoclonal
antibody against CD30, MAB229 (R&D Systems; Clone
81337), was used to examine CD30 expression (Figure 5A,
middle panel). Under the same conditions, recognition by
the Ber-H2 antibody was only slightly affected (Figure 5A,
lower panel and Figure 5B, third column), indicating that
Trx1-mediated disulﬁde bond reduction (and possibly rear-
rangement) induces a structural alteration in the CD30 ecto-
domain, which disrupts or conceals the Ki-1 epitope.
Pursuant to the observation that recognition of CD30 by
antibodies Ki-1 and MAB229 is affected by CD30 redox state,
we used ﬂow cytometry to analyze the response of CD30 to
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Figure 4 Trx1 discriminates between CD30 and other receptors with CRDs. (A) LCL-721.220 B cells were incubated with Trx1(CSAAA)
and disulﬁde-linked Trx1 complexes were analyzed by anti-CD95 immunoblotting. (B) A431 epithelial carcinoma cells were incubated
with Trx1(CSAAA) and complexes were analyzed by anti-EGFR immunoblotting. Cellular lysate was included as control. (C) HeLa cells
were transiently transfected with an expression construct for human CD30 or empty vector incubated with Trx1(CSAAA) and analyzed
by immunoﬂuorescence microscopy using CD30- and Trx1-speciﬁc antibodies (scale bar, 20mm). (D) HeLa cells were transiently transfected
with expression constructs for human CD30 or CD95, treated as described in (C) and analyzed by immunoﬂuorescence microscopy using
CD30-, Trx1- and CD95-speciﬁc antibodies (scale bar, 20mm). (E) RMA mouse lymphoma cells were incubated with Trx1(CSAAA) or
Trx1(CCAAA). Disulﬁde-linked Trx1 complexes were analyzed by anti-mouse CD30 (mCD30) immunoblotting under non-reducing and
reducing conditions. The disulﬁde-linked Trx1-mCD30 complex and monomeric mCD30 are indicated. The additional band of higher molecular
weight has not been further characterized but might represent a conjugate between Trx1 and a dimer of mCD30.
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inﬂuence antibody reactivity of CD30 (data not shown).
When reduced Trx1 was applied in the absence of a regener-
ating system, a conformational change in CD30 could be
observed, but remained incomplete (data not shown).
Complete and sustained loss of antibody reactivity required
a source of reducing equivalents for the oxidoreductase. Both
DTT and Trx reductase (TrxR)/NADPH were found to be
effective as regenerating systems. Importantly, neither DTT
nor TrxR/NADPH had an effect when applied in the absence
of Trx1 (Figure 5A, middle panel and data not shown). Wild-type
Grx1 (Figure 5C, left panel) and the redox-inactive mutant
of Trx1 (Figure 5C, middle panel) did not alter the
redox-sensitive CD30 epitopes. Other cell surface receptors,
for example CD28, analyzed in parallel on the same cells
were unaffected by Trx1 treatment (Figure 5C, right panel).
Loss of CD30 antibody recognition typically occurred within
minutes (Figure 5D, upper panel). Testing the inﬂuence of
Trx1 concentration under the same conditions, consistent
effects on CD30 conformation became evident at concentra-
tions around 100nM (Figure 5D, lower panel).
Trx1-mediated disulﬁde exchange interferes with CD30
receptor–ligand interactions
The observation that antibody binding to CD30 is inﬂuenced
by Trx1 suggested a redox-dependent conformational change
within the CD30 ectodomain. To test whether Trx1-mediated
reduction of CD30 inﬂuences binding of CD30 to its ligand
(CD30L), we analyzed the interaction between CD30 and
recombinant soluble CD30L (sCD30L) on the cell surface
by ﬂow cytometry. A brief incubation of CD30
þHodgkin’s
lymphoma HDLM-2 cells with wild-type Trx1 led to a substantial
loss in CD30L binding to the cell surface (Figure 6A).
A similar result was obtained for the large granular lymphoma
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Figure 5 Trx1 catalyzes disulﬁde bond reduction within the CD30 ectodomain. (A) CCRF-CEM Tcells were left untreated or treated with active
(CCAAA/CCCCC) or inactive Trx1 (SSAAA) in the presence of DTTas a regenerating system or with DTTonly. Cell surface CD30 was analyzed
by ﬂow cytometry using three different anti-CD30 antibodies (Ki-1: upper panel; MAB229: middle panel; Ber-H2: lower panel). PE-labeled
secondary antibody only was included as control. Untreated cells are shown in gray. (B) HeLa cells were transiently transfected with a CD30
expression vector and either left untreated or treated with active (CCAAA) or inactive Trx1 (SSAAA) in the presence of DTT. Cells were
analyzed by immunoﬂuorescence microscopy using CD30-speciﬁc antibodies Ki-1 and Ber-H2 (scale bar, 20mm). (C) CCRF-CEM cells were left
untreated or treated with different Trx1 constructs or wild-type Grx1 as indicated. Cell surface CD30 was analyzed by anti-CD30 antibody
MAB229 (left and middle panel). Alternatively, cells treated with wild-type Trx1 were analyzed by PE-conjugated anti-CD28 antibody (right
panel). Untreated cells are shown in gray. (D) CCRF-CEM cells were treated with 5mM active Trx1 for different time points (upper graph) or
with different Trx1 concentrations (lower graph) for 30min. Cells were analyzed as described in (C).
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evident in the absence of an exogenously added reducing
system (Supplementary Figure S5), thus demonstrating that
under the given conditions Trx1–substrate interactions are
not limited by oxidative inactivation.
As shown by ﬂuorescence microscopy, sCD30L binds to
the surface of CD30-transfected HeLa cells and colocalizes
with its receptor (Figure 6B, upper row). Treatment of HeLa
cells with Trx1(CCAAA) (Figure 6B, middle row) but not a
redox-inactive mutant (Figure 6B, lower row) strongly inter-
feres with CD30L binding and colocalization.
Trx1-mediated reducing activity interrupts
agonist-induced CD30 signaling in YT cells
Given its inﬂuence on ligand binding, we reasoned that Trx1
might interfere with CD30-mediated signaling. To test
whether Trx1-mediated conformational alteration of CD30
affects CD30-dependent cellular responses, we made use of
the YT large granular lymphoma line that has previously
been used to study signals emanating from CD30 and to
deﬁne the genes regulated by such signals (Muta et al, 2000).
Consistent with previous results (Bowen et al, 1993), we
observed that stimulation of CD30 with either agonistic
antibodies or sCD30L led to upregulation of the IL-2Ra
chain (CD25) within 24h (Figure 7A, lower panel, compare
columns 3, 4 and 7). Treatment of YTcells with Trx1(CCAAA)
(but not with redox-inactive Trx1) prevented CD25 upregula-
tion (Figure 7A, lower panel, columns 5 and 8), concomitant
with the redox change in CD30 (Figure 7A, upper panel,
column 4), thus demonstrating that the redox interaction
between Trx1 and CD30 has a pronounced inﬂuence on
CD30-mediated gene expression.
YT cells respond to CD30 signals by downregulating the
expression of cytotoxic effector molecules, including FasL,
thus decreasing their cytotoxicity against Fas-expressing
target cells (Bowen et al, 1993; Muta et al, 2000). To test if
Trx1 inﬂuences CD30-mediated suppression of cytotoxicity,
we treated YTcells with Trx1(CCAAA) or Trx1(SSAAA) before
stimulation with agonistic anti-CD30 antibody and quanti-
ﬁed cytotoxicity against Cr-labeled Raji cells. Upon CD30
stimulation, cytotoxicity was markedly reduced (Figure 7B,
compare columns 1 and 4). The decrease in cytotoxicity was
completely reversed by Trx1(CCAAA) but not the catalytically
inactive mutant (SSAAA) (Figure 7B, columns 5 and 6). As
judged by RT–PCR, changes in cytotoxicity correlated with
changes in FasL mRNA expression (Figure 7B, lower panel).
These results conﬁrm that the catalytic activity of Trx1
modulates CD30-dependent changes in cellular behavior
and function.
Discussion
Accumulating evidence indicates that the reduction and
rearrangement of disulﬁde bonds constitutes a mechanism
controlling protein function on the cell surface (Hogg, 2003).
The idea that disulﬁde bonds can act as dynamical redox
switches, speciﬁcally operated by secreted redox catalysts,
represents a novel concept in signal transduction (Jordan and
Gibbins, 2006). However, technical difﬁculties in detecting
and analyzing individual disulﬁde rearrangements on the cell
surface have made progress slow.
Trx1 is recognized as one of the most important regulators
of cellular and organismal redox homeostasis (Gromer et al,
2004). In particular, intracellular Trx1 counteracts oxidative
stress, promotes cell growth and inhibits apoptosis. Under
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Figure 6 Trx1-mediated disulﬁde bond reduction in CD30 prevents binding of the CD30L. (A) HDLM-2 Hodgkin cells were either left untreated
or treated with wild-type Trx1 in the presence of DTTas a regenerating system. After washing, cells were incubated with recombinant CD30L-
His10 as indicated. Bound CD30L was detected by ﬂow cytometry using anti-polyHis antibody. Cells incubated with anti-polyHis antibody only
were used as control. Unstained cells are shown in gray. (B) HeLa cells were transiently transfected with an expression construct for CD30 and
either left untreated or treated with active (CCAAA) or inactive Trx1 (SSAAA) in the presence of DTT. After washing, cells were incubated with
recombinant CD30L-His10. CD30L bound to the cell surface was analyzed by immunoﬂuorescence microscopy using anti-CD30L antibody
(scale bar, 20mm).
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accumulates at sites of inﬂammation (Nordberg and Arner,
2001). Numerous studies have reported that secretory Trx1
inﬂuences effector functions and proliferation of lymphocytes
(Nakamura et al, 1997). However, proteins and pathways
coupling extracellular Trx1 redox activity to deﬁned cellular
responses have remained unknown. In this study, we ad-
dressed the question regarding which lymphocyte surface
receptors are targeted and regulated by the redox activity of
extracellular Trx1.
For this purpose, we made use of a mechanism-based
kinetic trapping approach to capture mixed disulﬁde inter-
mediates formed between exogenous Trx1 and its target
proteins on the cell surface of living cells. Activity-based
techniques offer the opportunity to identify interactions too
short-lived to be detectable by conventional methods. To our
knowledge, this is the ﬁrst reported application of kinetic
trapping to identify novel target proteins of mammalian Trx1
and the ﬁrst application of this technique to the surface of
intact cells. We demonstrate that Trx1 interacts with intra-
and extracellular target proteins in a highly selective manner,
guided by speciﬁc protein–protein recognition rather than
random encounters with disulﬁde bonds.
Applying the approach to the surface of cell lines repre-
sentative of the lymphoid lineage, we observed that Trx1
basically targets a single cell surface protein, subsequently
identiﬁed as TNF receptor superfamily member 8, also
known as CD30. The pronounced preference of Trx1 for one
particular target protein might seem surprising, but could be
due to the fact that we assessed Trx1 reactivity of proteins as
they are embedded in their natural microenvironment,
namely the intact surface of the active plasma membrane of
living cells. It is conceivable that protein disulﬁde exchange
interactions are limited and controlled by their native context
and location.
To scrutinize the speciﬁcity of the observed interaction, we
asked if the preference of Trx1 for CD30 might be caused by
an unusual density of disulﬁde bonds within CD30 and/or
exceptional cell surface expression levels. Although the CD30
ectodomain harbors a signiﬁcant number of predicted dis-
ulﬁde bridges within CRDs, it does not appear to be unusual
in terms of disulﬁde bond composition/density when com-
pared to other members of the superfamily. When tested
experimentally, Trx1 failed to interact with other CRD-con-
taining proteins, including the EGFR featuring a total of 25
ectodomain disulﬁde bonds. The preference for CD30 could
not be explained by exceptional surface expression levels
either. While Hodgkin’s disease cell lines typically express
high levels of CD30, other cell lines including LCL-721.220 or
CCRF-CEM show at least 20- to 100-fold lower expression as
determined by ﬂow cytometry, yet the same selective target-
ing was observed. Conversely, ectopic overexpression of
several related TNFR superfamily members in HeLa cells
did not lead to their interaction with Trx1, yet CD30 strongly
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Figure 7 Trx1 controls CD30-mediated functional changes in lymphoma cells. (A) Trx1 inhibits CD30-mediated changes in gene expression.
YT large granular lymphoma cells were left untreated or treated with active (CCAAA) or inactive Trx1 (SSAAA) in the presence of TrxR/NADPH
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Redox regulation of TNFRSF8/CD30
U Schwertassek et al
The EMBO Journal VOL 26 | NO 13 | 2007 &2007 European Molecular Biology Organization 3094interacted on the same cells under the same conditions.
Consistent with these ﬁndings, recent experiments demon-
strate that Trx1 targets a particular site within the CD30
ectodomain (Y Balmer and TP Dick, unpublished data).
To facilitate identiﬁcation of low-abundance cell surface
proteins, in vitro trapping experiments were typically per-
formed using Trx1 concentrations of 1–3mM. However, when
disulﬁde exchange was subsequently tested at lower concen-
trations, Trx1(CSAAA) concentrations in the low nanomolar
range (4–40nM) were found to give rise to the formation of
proportional amounts of Trx1-CD30 mixed disulﬁde inter-
mediates (Figure 3B), thus demonstrating that the observed
interaction is compatible with the expected physiological
concentration range of secretory Trx1 (see below).
Wild-type Trx1 is known to act as a multiple-turnover
catalyst if a suitable reducing system and electron source is
provided for its regeneration. In agreement with these con-
siderations, we observed that sustained reduction of CD30 in
cell culture requires a Trx1 regenerating system. Using ﬂow
cytometry to monitor conformational changes in the CD30
ectodomain, CD30 was found to respond to Trx1 concentra-
tions in the nanomolar range, starting at around 100nM
(Figure 5E, lower panel). However, the minimal Trx1 con-
centration required for sustained CD30 reduction might
be substantially lower in speciﬁc environments, which are
efﬁcient in delivering reducing equivalents and preventing
oxidative inactivation of Trx1.
At present, it is not clear how extracellular Trx1 is regen-
erated in vivo. Despite the overall oxidizing character of the
extracellular compartment, reductive processes are known to
take place on the cell surface. On the one hand, there is long-
standing evidence for the existence of transplasma membrane
redox systems delivering electrons to the cell surface (Crane
et al, 1985). On the other hand, Trx1 may be regenerated by
co-secreted reductants, as Trx1 secretion in DC-Tco-culture is
accompanied by the release of reduced cysteine and the
creation of a reducing microenvironment between interacting
cells (Angelini et al, 2002). In addition, TrxR was found to be
secreted by activated monocytes and might be part of an
extracellular Trx1 reducing system (Soderberg et al, 2000).
The concentration of Trx1 in human plasma is in the low
nanomolar range (1–5nM), and is found to be elevated
several-fold under inﬂammatory conditions (Yoshida et al,
1999). However, plasma Trx1 is oxidized and appears to
represent systemic dilution of Trx1 previously released within
tissues. Accordingly, local tissue concentrations of secretory
Trx1, for example, within activated lymph nodes, are ex-
pected to be markedly higher than in plasma. Overall Trx1
concentrations in mammalian tissues can be as high as 20mM
(Gromer et al, 2004). Certain Trx1-secreting cell types,
including macrophages and dendritic cells, distinctly upregu-
late expression of Trx1 upon activation (Angelini et al, 2002).
In vitro studies of Trx1 secretion suggest that a substantial
fraction of intracellular Trx1 can be released within a few
hours (Rubartelli et al, 1992). Although direct measurements
of extracellular Trx1 within tissues are not available, physio-
logically relevant extracellular Trx1 concentrations may well
reach into the upper nanomolar, if not lower micromolar
range.
We found that Trx1-mediated disulﬁde reduction changes
the conformation and functional properties of the CD30
ectodomain. In the reduced state, CD30 lost its ability to
interact with its cognate ligand CD30L or agonistic antibo-
dies. The presence of catalytically active Trx1 impeded
CD30-dependent signaling in the YT lymphoma cell line,
as demonstrated by its effect on CD25 and FasL expression,
as well as its inﬂuence on cytotoxicity against Fas-expressing
target cells.
The physiological role of the CD30-CD30L system has
remained unclear. In vitro studies focusing on CD30
þ lymphoid
malignancies showed that triggering of CD30 signaling can
induce either proliferation, activation, growth arrest or apop-
tosis, depending on cell type and stimulatory conditions
(Schneider and Hubinger, 2002). In vivo, cell surface expres-
sion of CD30 appears to be tightly regulated and restricted to
B and T lymphocytes undergoing activation in lymphoid
tissues. It has been proposed that CD30 provides prolifera-
tion and/or survival signals during lymphocyte responses
(Croft, 2003).
Under inﬂammatory conditions, CD30 expression is mark-
edly induced. In vivo activation of CD30 can be monitored by
the release of sCD30, shed from the plasma membrane upon
CD30L binding (Hansen et al, 2000). Similar to serum Trx1,
serum sCD30 is increased in infection, autoimmunity and
allergy, for example systemic lupus erythematosus, rheuma-
toid arthritis and atopic dermatitis (Horie and Watanabe,
1998). Both Trx1 and CD30 appear to play a role in the
regulation of the antiviral inﬂammatory response. Both Trx1
secretion and CD30 expression have been associated with
virally transformed lymphocytes. Elevated levels of sCD30
occur during viral infection. Likewise, viral infection leads to
elevated Trx1 plasma levels and several studies indicate that
secreted Trx1 modulates the antiviral inﬂammatory process
(Nakamura et al, 2001b, 2002).
In this study, we have identiﬁed an enzyme–substrate
relationship between Trx1 and CD30, a receptor of activated
lymphocytes involved in the regulation of inﬂammation. As
lymphocytes migrate between different microenvironments,
it is conceivable that Trx1 catalyzes disulﬁde exchange
dynamically, activating or inactivating the CD30 pathway in
response to the redox environment. The interaction between
Trx1 and CD30 might represent a regulatory link between
oxidative stress and lymphocyte function. Understanding of
this relationship in vivo awaits the generation of suitable
experimental tools.
Materials and methods
Cell culture
BL-41, CCRF-CEM, HDLM-2, Jurkat, RMA and U937 cells were
cultured in RPMI 1640 (Gibco) supplemented with 10% heat-
inactivated fetal bovine serum, 2mM L-glutamine, 100U/ml
penicillin and 100mg/ml streptomycin (Gibco). LCL-721.220 and
YT cells were cultured in IMDM (Gibco), HeLa and A431 cells in
DMEM (Gibco) with the same supplements.
Substrate trapping
Depending on the type of experiment, recombinant trapping mutant
was applied to cytosolic preparations, human serum ultraﬁltrate or
intact cells. A detailed description of the different substrate trapping
protocols is provided as Supplementary information.
Analysis of CD30 redox state by ﬂow cytometry
For reduction of cell surface CD30, 2.5 10
5 cells were incubated
with 5mM Trx1 together with 200mM DTT or 100nM human Trx
reductase (TrxR)/500mM NADPH for 30min at 41C. To monitor
reduction of cell surface CD30, cells were stained with anti-human
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CD30 monoclonal antibody Ki-1 (Santa Cruz) or anti-human CD30
monoclonal antibody Ber-H2 (DakoCytomation) followed by
incubation with R-PE-conjugated goat F(ab’)2 anti-mouse Ig’s
(Biosource). For control, cells were stained with R-PE-conjugated
anti-human CD28 monoclonal antibody (BD Pharmingen). Cells
were analyzed using a FACSCalibur (Becton Dickinson) and
CellQuest software.
CD30L binding assay
A total of 2.5 10
5 cells were incubated with 5mM Trx1 (SBP-
CCCCC) and 200mM DTT for 30min at 371C, washed three times
and incubated with 250ng/ml recombinant CD30L-His10 (R&D
Systems) for 10min at RT. After washing, cells were stained with
anti-polyHis monoclonal antibody (Sigma) followed by incubation
with R-PE-conjugated goat F(ab’)2 anti-mouse Ig’s (Biosource).
Immunoﬂuorescence microscopy
HeLa cells were seeded on coverslips and transfected with
expression constructs using CaCl2 precipitation. After 2 days,
transfected cells were ﬁxed with 3% formaldehyde and 2% sucrose
in PBS for 7min at RT. Fixed cells were washed three times with
PBS and incubated with different Trx1 constructs or recombinant
CD30L (R&D Systems). Proteins were visualized using appropriate
primary antibodies (Anti-CD30L polyclonal antibody (R&D Systems),
anti-CD30 monoclonal antibodies Ki-1 (Santa Cruz) or Ber-H2
(DakoCytomation), anti-CD95 monoclonal antibody (a kind gift from
Dr P Krammer), anti-Trx1 polyclonal antibody (M Preuss and
TP Dick, unpublished) followed by FITC-conjugated anti-goat IgG,
FITC-conjugated anti-rabbit IgG or TRITC-conjugated anti-mouse
IgG and analyzed with a Nikon C1Si confocal microscope.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
Acknowledgements
We thank Carmen Mader for technical assistance and Dr Shrikesh
Sachdev for critical reading of the manuscript. We thank Dr Hinrich
Hansen, Dr Peter Krammer, Dr Stefan Gromer, Dr Lars-Oliver Klotz,
Dr Thomas Ruppert and Dr Ulrike Engel for reagents and assistance.
Support for this work was provided by an European Commission
Marie Curie Excellence Grant (TPD) and the Boehringer Ingelheim
Fonds (US).
References
Angelini G, Gardella S, Ardy M, Ciriolo MR, Filomeni G, Di Trapani
G, Clarke F, Sitia R, Rubartelli A (2002) Antigen-presenting
dendritic cells provide the reducing extracellular microenviron-
ment required for T lymphocyte activation. Proc Natl Acad Sci
USA 99: 1491–1496
Bertini R, Howard OM, Dong HF, Oppenheim JJ, Bizzarri C, Sergi R,
Caselli G, Pagliei S, Romines B, Wilshire JA, Mengozzi M,
Nakamura H, Yodoi J, Pekkari K, Gurunath R, Holmgren A,
Herzenberg LA, Ghezzi P (1999) Thioredoxin, a redox enzyme
released in infection and inﬂammation, is a unique chemoattractant
for neutrophils, monocytes, and Tcells. JE x pM e d189: 1783–1789
Bodmer JL, Schneider P, Tschopp J (2002) The molecular architecture
of the TNF superfamily. Trends Biochem Sci 27: 19–26
Bowen MA, Olsen KJ, Cheng L, Avila D, Podack ER (1993)
Functional effects of CD30 on a large granular lymphoma
cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and
IL-2R, and induction of homotypic aggregation. J Immunol 151:
5896–5906
Burgess SC, Young JR, Baaten BJ, Hunt L, Ross LN, Parcells MS,
Kumar PM, Tregaskes CA, Lee LF, Davison TF (2004) Marek’s
disease is a natural model for lymphomas overexpressing
Hodgkin’s disease antigen (CD30). Proc Natl Acad Sci USA 101:
13879–13884
Casagrande S, Bonetto V, Fratelli M, Gianazza E, Eberini I,
Massignan T, Salmona M, Chang G, Holmgren A, Ghezzi P
(2002) Glutathionylation of human thioredoxin: a possible crosstalk
between the glutathione and thioredoxin systems. Proc Natl Acad
Sci USA 99: 9745–9749
Chen JH, Chang YW, Yao CW, Chiueh TS, Huang SC, Chien KY, Chen
A, Chang FY, Wong CH, Chen YJ (2004) Plasma proteome of
severe acute respiratory syndrome analyzed by two-dimensional
gel electrophoresis and mass spectrometry. Proc Natl Acad Sci
USA 101: 17039–17044
Crane FL, Sun IL, Clark MG, Grebing C, Low H (1985) Transplasma-
membrane redox systems in growth and development. Biochim
Biophys Acta 811: 233–264
Croft M (2003) Co-stimulatory members of the TNFR family: keys to
effective T-cell immunity? Nat Rev Immunol 3: 609–620
de Paiva A, Poulain B, Lawrence GW, Shone CC, Tauc L, Dolly JO
(1993) A role for the interchain disulﬁde or its participating thiols
in the internalization of botulinum neurotoxin A revealed by a
toxin derivative that binds to ecto-acceptors and inhibits trans-
mitter release intracellularly. J Biol Chem 268: 20838–20844
Dick TP, Cresswell P (2002) Thiol oxidation and reduction in major
histocompatibility complex class I-restricted antigen processing
and presentation. Methods Enzymol 348: 49–54
Dick TP, Bangia N, Peaper DR, Cresswell P (2002) Disulﬁde bond
isomerization and the assembly of MHC class I-peptide com-
plexes. Immunity 16: 87–98
Essex DW (2004) The role of thiols and disulﬁdes in platelet
function. Antioxid Redox Signal 6: 736–746
Gill GN, Lazar CS (1981) Increased phosphotyrosine content and
inhibition of proliferation in EGF-treated A431 cells. Nature 293:
305–307
Greene JL, Leytze GM, Emswiler J, Peach R, Bajorath J, Cosand W,
Linsley PS (1996) Covalent dimerization of CD28/CTLA-4 and
oligomerization of CD80/CD86 regulate T cell costimulatory
interactions. J Biol Chem 271: 26762–26771
Gromer S, Urig S, Becker K (2004) The thioredoxin system—from
science to clinic. Med Res Rev 24: 40–89
Hansen HP, Dietrich S, Kisseleva T, Mokros T, Mentlein R, Lange
HH, Murphy G, Lemke H (2000) CD30 shedding from Karpas 299
lymphoma cells is mediated by TNF-alpha-converting enzyme.
J Immunol 165: 6703–6709
Hogg PJ (2003) Disulﬁde bonds as switches for protein function.
Trends Biochem Sci 28: 210–214
Horie R, Watanabe T (1998) CD30: expression and function in
health and disease. Semin Immunol 10: 457–470
Jordan PA, Gibbins JM (2006) Extracellular disulﬁde exchange
and the regulation of cellular function. Antioxid Redox Signal 8:
312–324
Lahav J, Wijnen EM, Hess O, Hamaia SW, Grifﬁths D, Makris M,
Knight CG, Essex DW, Farndale RW (2003) Enzymatically cata-
lyzed disulﬁde exchange is required for platelet adhesion to
collagen via integrin alpha2beta1. Blood 102: 2085–2092
Markovic I, Stantchev TS, Fields KH, Tiffany LJ, Tomic M,
Weiss CD, Broder CC, Strebel K, Clouse KA (2004) Thiol/
disulﬁde exchange is a prerequisite for CXCR4-tropic HIV-1
envelope-mediated T-cell fusion during viral entry. Blood 103:
1586–1594
Matthias LJ, Yam PT, Jiang XM, Vandegraaff N, Li P, Poumbourios P,
Donoghue N, Hogg PJ (2002) Disulﬁde exchange in domain 2 of
CD4 is required for entry of HIV-1. Nat Immunol 3: 727–732
Motohashi K, Kondoh A, Stumpp MT, Hisabori T (2001)
Comprehensive survey of proteins targeted by chloroplast thior-
edoxin. Proc Natl Acad Sci USA 98: 11224–11229
Muta H, Boise LH, Fang L, Podack ER (2000) CD30 signals integrate
expression of cytotoxic effector molecules, lymphocyte trafﬁcking
signals, and signals for proliferation and apoptosis. J Immunol
165: 5105–5111
Nakamura H, De Rosa SC, Yodoi J, Holmgren A, Ghezzi P,
Herzenberg LA (2001a) Chronic elevation of plasma thioredoxin:
inhibition of chemotaxis and curtailment of life expectancy in
AIDS. Proc Natl Acad Sci USA 98: 2688–2693
Nakamura H, Herzenberg LA, Bai J, Araya S, Kondo N, Nishinaka Y,
Yodoi J (2001b) Circulating thioredoxin suppresses lipopolysac-
charide-induced neutrophil chemotaxis. Proc Natl Acad Sci USA
98: 15143–15148
Redox regulation of TNFRSF8/CD30
U Schwertassek et al
The EMBO Journal VOL 26 | NO 13 | 2007 &2007 European Molecular Biology Organization 3096Nakamura H, Masutani H, Yodoi J (2002) Redox imbalance and its
control in HIV infection. Antioxid Redox Signal 4: 455–464
Nakamura H, Nakamura K, Yodoi J (1997) Redox regulation of
cellular activation. Annu Rev Immunol 15: 351–369
Nordberg J, Arner ES (2001) Reactive oxygen species, antioxidants,
and the mammalian thioredoxin system. Free Radic Biol Med 31:
1287–1312
Peltoniemi MJ, Karala AR, Jurvansuu JK, Kinnula VL, Ruddock LW
(2006) Insights into deglutathionylation reactions: Different inter-
mediates in the glutaredoxin and protein disulphide isomerase
catalysed reactions are deﬁned by the gamma-linkage present in
glutathione. J Biol Chem 281: 33107–33114
Powis G, Montfort WR (2001) Properties and biological activities of
thioredoxins. Annu Rev Biophys Biomol Struct 30: 421–455
Rubartelli A, Bajetto A, Allavena G, Wollman E, Sitia R (1992)
Secretion of thioredoxin by normal and neoplastic cells through a
leaderless secretory pathway. J Biol Chem 267: 24161–24164
Sanders DA (2000) Sulfhydryl involvement in fusion mechanisms.
Subcell Biochem 34: 483–514
Schneider C, Hubinger G (2002) Pleiotropic signal transduction
mediated by human CD30: a member of the tumor necrosis factor
receptor (TNFR) family. Leuk Lymphoma 43: 1355–1366
Soderberg A, Sahaf B, Rosen A (2000) Thioredoxin reductase,
a redox-active selenoprotein, is secreted by normal and neo-
plastic cells: presence in human plasma. Cancer Res 60:
2281–2289
Tagaya Y, Maeda Y, Mitsui A, Kondo N, Matsui H, Hamuro J, Brown
N, Arai K, Yokota T, Wakasugi H, Yodoi J (1989) ATL-derived
factor (ADF), an IL-2 receptor/Tac inducer homologous to thior-
edoxin; possible involvement of dithiol-reduction in the IL-2
receptor induction. EMBO J 8: 757–764
Tagaya Y, Okada M, Sugie K, Kasahara T, Kondo N, Hamuro J,
Matsushima K, Dinarello CA, Yodoi J (1988) IL-2 receptor
(p55)/Tac-inducing factor. Puriﬁcation and characterization of
adult T cell leukemia-derived factor. J Immunol 140: 2614–2620
Wakasugi N, Tagaya Y, Wakasugi H, Mitsui A, Maeda M, Yodoi J,
Tursz T (1990) Adult T-cell leukemia-derived factor/thioredoxin,
produced by both human T-lymphotropic virus type I- and
Epstein–Barr virus-transformed lymphocytes, acts as an auto-
crine growth factor and synergizes with interleukin 1 and inter-
leukin 2. Proc Natl Acad Sci USA 87: 8282–8286
Watson WH, Pohl J, Montfort WR, Stuchlik O, Reed MS, Powis G,
Jones DP (2003) Redox potential of human thioredoxin 1 and
identiﬁcation of a second dithiol/disulﬁde motif. J Biol Chem 278:
33408–33415
Yang Y, Jao S, Nanduri S, Starke DW, Mieyal JJ, Qin J (1998)
Reactivity of the human thioltransferase (glutaredoxin) C7S,
C25S, C78S, C82S mutant and NMR solution structure of its
glutathionyl mixed disulﬁde intermediate reﬂect catalytic speci-
ﬁcity. Biochemistry 37: 17145–17156
Yoshida S, Katoh T, Tetsuka T, Uno K, Matsui N, Okamoto T
(1999) Involvement of thioredoxin in rheumatoid arthritis:
its costimulatory roles in the TNF-alpha-induced production of
IL-6 and IL-8 from cultured synovial ﬁbroblasts. J Immunol 163:
351–358
The EMBO Journal is published by Nature
Publishing Group on behalf of European
Molecular Biology Organization. This article is licensed
under a Creative Commons Attribution License <http://
creativecommons.org/licenses/by/2.5/>
Redox regulation of TNFRSF8/CD30
U Schwertassek et al
&2007 European Molecular Biology Organization The EMBO Journal VOL 26 | NO 13 | 2007 3097